Journal of Lipid Research, Vol 38, 2281-2288, Copyright © 1997 by Lipid Research, Inc.

ARTICLES

Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins

R Guerra, B Zhao, V Mooser, D Stafforini, JM Johnston and JC Cohen
Department of Statistical Science, Southern Methodist University, Dallas, TX 75275, USA.

Plasma platelet-activating factor acetylhydrolase (PAF-AH) is the enzyme that inactivates PAF (1-alkyl-2-acetyl-sn-glycero-3- phosphocholine). We determined the relative contributions of genetic and environmental factors to variation in plasma PAF-AH activity in 240 individuals from 60 nuclear families. Regression of mean-offspring PAF- AH activity on the mid-parent value indicated that 62% of the variation in plasma PAF-AH activity was heritable. Spousal values were weakly negatively correlated, indicating that familial aggregation of PAF-AH activity is due to genetic rather than to environmental factors. Among normolipidemic individuals, plasma PAF-AH activity was strongly correlated with the plasma concentration of low density lipoprotein cholesterol (LDL-C), and treatment with lovastatin resulted in proportional decreases in plasma PAF-AH activity and LDL-C concentrations. To further elucidate the relationship between PAF-AH and plasma concentrations of LDL, plasma PAF-AH activity was measured in families with well-defined, monogenic disorders of LDL metabolism. Plasma PAF-AH activity cosegregated with plasma LDL-C concentrations in familial hypercholesterolemia, but not in familial hypobetalipoproteinemia. We speculate that the rate of removal of LDL from the circulation may determine the clearance rate of PAF-AH, thereby modulating the activity of PAF-AH in blood.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Vinson, M. C. Mahaney, V. P. Diego, L. A. Cox, J. Rogers, J. L. VandeBerg, and D. L. Rainwater Genotype-by-diet effects on co-variation in Lp-PLA2 activity and LDL-cholesterol concentration in baboons fed an atherogenic diet J. Lipid Res., June 1, 2008; 49(6): 1295 - 1302. [Abstract] [Full Text] [PDF]

				B. S. Sutton, D. R. Crosslin, S. H. Shah, S. C. Nelson, A. Bassil, A. B. Hale, C. Haynes, P. J. Goldschmidt-Clermont, J. M. Vance, D. Seo, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets Hum. Mol. Genet., May 1, 2008; 17(9): 1318 - 1328. [Abstract] [Full Text] [PDF]

				C. De Vriese, M. Hacquebard, F. Gregoire, Y. Carpentier, and C. Delporte Ghrelin Interacts with Human Plasma Lipoproteins Endocrinology, May 1, 2007; 148(5): 2355 - 2362. [Abstract] [Full Text] [PDF]

				Y. Jang, O. Y. Kim, S. J. Koh, J. S. Chae, Y. G. Ko, J. Y. Kim, H. Cho, T.-S. Jeong, W. S. Lee, J. M. Ordovas, et al. The Val279Phe Variant of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Catalytic Activities and Cardiovascular Disease in Korean Men J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3521 - 3527. [Abstract] [Full Text] [PDF]

				E. C. Papavasiliou, C. Gouva, K. C. Siamopoulos, and A. D. Tselepis PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1270 - 1277. [Abstract] [Full Text] [PDF]

				C. Iribarren, M. D. Gross, J. A. Darbinian, D. R. Jacobs Jr, S. Sidney, and C. M. Loria Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults: The CARDIA Study Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 216 - 221. [Abstract] [Full Text] [PDF]

				S. Campo, M. A. Sardo, A. Bitto, A. Bonaiuto, G. Trimarchi, M. Bonaiuto, M. Castaldo, C. Saitta, S. Cristadoro, and A. Saitta Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals Clin. Chem., November 1, 2004; 50(11): 2077 - 2082. [Abstract] [Full Text] [PDF]

				V. Tsimihodimos, A. Kostoula, A. Kakafika, E. Bairaktari, A. D. Tselepis, D. P. Mikhailidis, and M. Elisaf Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 27 - 33. [Abstract] [PDF]

				V. Tsimihodimos, S.-A. P. Karabina, A. P. Tambaki, E. Bairaktari, G. Miltiadous, J. A. Goudevenos, M. A. Cariolou, M. J. Chapman, A. D. Tselepis, and M. Elisaf Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia J. Lipid Res., February 1, 2002; 43(2): 256 - 263. [Abstract] [Full Text] [PDF]

				V. Tsimihodimos, S.-A. P. Karabina, A. P. Tambaki, E. Bairaktari, J. A. Goudevenos, M. J. Chapman, M. Elisaf, and A. D. Tselepis Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 306 - 311. [Abstract] [Full Text] [PDF]

				T. Hakkinen, J. S. Luoma, M. O. Hiltunen, C. H. Macphee, K. J. Milliner, L. Patel, S. Q. Rice, D. G. Tew, K. Karkola, and S. Yla-Herttuala Lipoprotein-Associated Phospholipase A2, Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2909 - 2917. [Abstract] [Full Text] [PDF]